Search

Your search keyword '"Potter, V."' showing total 1,963 results

Search Constraints

Start Over You searched for: Author "Potter, V." Remove constraint Author: "Potter, V."
1,963 results on '"Potter, V."'

Search Results

1. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT

2. Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer: A Nested Case-control Matched Analysis of an International, Multi-centre, Randomised Controlled Trial (FOxTROT)

4. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT

6. EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

8. P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION

9. Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with Myelodysplastic Syndromes or secondary Acute Myeloid Leukemia (vol 11,& nbsp;584520, 2021)

19. PH-0329 Feasibility and outcome of bridging RT pre CAR-T in DLBCL in one centre with a wide referral network

24. Total body irradiation plus fludarabine compared to busulfan plus fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

30. S103 Baseline CT thorax in patients undergoing allogeneic haematopoetic stem-cell transplantation and risk of invasive fungal disease- a prospective 5-year study

31. Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

33. Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients – the Diadem Study from the Chronic Malignancies Working Party of the EBMT

38. Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation

39. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

40. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells

41. DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY

43. Cardiopoietic cell therapy for advanced ischemic heart failure : results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

44. Purpose and Function of the University

45. CAR T treatment access and outcomes in patients with large B‐cell lymphoma according to ethnicity and socioeconomic deprivation.

46. Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer

47. Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Catalog

Books, media, physical & digital resources